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Background: Natural products from plants have been proven to be important resources of antitumor agents. In
this study, we exploited the antitumor activity of (E)-3-(4-chlorophenyl)-N-(7-hydroxy-6-methoxy-2-oxo-2H-
chromen-3-yl) acrylamide (SC-III3), a newly synthesized derivative of scopoletin, by in vitro and in vivo experiments.
Methods: Human hepatocellular carcinoma cell line HepG2 cells and xenograft of HepG2 cells in BALB/c nude
mice were used to investigate the effects of SC-III3 on hepatocellular cancers. Cell cycle arrest and apoptosis were
analyzed by flow cytometry. Cell cycle arrest, apoptosis and ATM-Chk pathway-related proteins were characterized
by western blot.
Results: SC-III3 selectively inhibited the viability of HepG2 cells without significant cytotoxicity against human
normal liver cells LO2. In mouse xenograft model of HepG2 cells, SC-III3 showed a marked inhibition of tumor
growth in a dose-dependent manner. Cell cycle analysis revealed that SC-III3 induced cells to accumulate in S
phase, which was accompanied by a marked decrease of the expressions of cyclin A, cyclin B, cyclin E and Cdk2
proteins, the crucial regulators of S phase cell cycle. SC-III3 treatment resulted in DNA breaks in HepG2 cells, which
might contribute to its S phase arrest. The S arrest and the activation of ATM-Chk1/Chk2-Cdc25A-Cdk2 pathways
induced by SC-III3 in HepG2 cells could be efficiently abrogated by pretreatments of either Ku55933 (an inhibitor of
ATM) or UCN-01 (an inhibitor of Chk1/Chk2). The activation of p53-p21 pathway by SC-III3 was also reversed by
Ku55933 treatment. SC-III3 led to significant accumulation of intracellular reactive oxygen species (ROS), a breaker of
DNA strand, in HepG2 cells but not LO2 cells. Pretreatment with N-acetyl-l-cysteine (NAC), a ROS scavenger, could
reverse SC-III3-caused ROS accumulation, DNA damage, activation of signal pathways relevant to DNA damage, S
phase arrest and cell viability decrease in HepG2 cells.
Conclusion: SC-III3 is able to efficiently inhibit the growth of hepatocellular carcinoma through inducing the
generation of intracellular ROS, DNA damage and consequent S phase arrest, but lack of significant cytotoxicity
against normal liver cells. This compound deserves further studies as a candidate of anticancer drugs.
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Figure 1 The chemical structure of SC-III3.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon solid tumor and the third largest cause of cancer-
related death worldwide [1,2]. Although a great achieve-
ment in HCC treatment has been acquired during the
past three decades, patients still experience a poor prog-
nosis because of the lack of effective therapeutic agents
[3,4]. Current therapeutic strategies for HCC, such as
surgical resection, liver transplantation and a few of
pharmaceutical interventions, fail to take an observable
effect [5,6]. Therefore, novel therapeutic strategies, in-
cluding the utilization of new targeted agents, com-
bination chemotherapy, and neoadjuvant therapy are
needed urgently for the effective management of hepato-
cellular carcinoma.
Intracellular reactive oxygen species (ROS) is deeply in-
volved in a great range of biological activities and disease
states, such as cell fate-death or survival, cancer, diabetes,
neurodegeneration and atherosclerosis [7]. At low to mo-
derate levels, ROS may contribute to tumor formation
either by acting as signaling molecules or by promoting
the mutation of genomic DNA. For instance, ROS can
stimulate the phosphorylations of p38 mitogen-activated
protein kinase (MAPK), extracellular signal-regulated
kinase (ERK) and JUN N-terminal kinase (JNK), which are
beneficial for tumor cell growth and survival. However, at
high levels, ROS will promote cell death and severe cellu-
lar damage such as DNA damage [8]. Furthermore, cancer
cells have higher ROS levels than normal cells. This aspect
provides a significant therapeutic window because cancer
cells are more sensitive than normal cells to agents that
induce further accumulation of ROS [9-11]. Therefore,
perturbing ROS homeostasis is considered as a new stra-
tegy for cancer treatment.
In response to DNA damage caused by high levels of
ROS, cell cycle checkpoints and a series effector kinases
should be activated, which thereby regulates the cellular
decision among cell cycle arrest, DNA repair, apoptosis
or other cell death modalities [12]. Ataxia telangiectasia-
mutated (ATM), ATM and RAD3-related (ATR) kinases
are two members of the phosphoinositide 3-kinase-
related protein kinase family that plays key role in DNA
damage response. Following the activation of these ki-
nases, the downstream effectors such as Chk1, Chk2 and
p53 are activated [13,14]. Then, activated Chk1 and
Chk2 result in the phosphorylations of their downstream
effectors such as Cdc25A, which regulate the activity of
Cdk2 by dephosphorylation on Tyr15 [15,16]. Cdk2-
cyclinA complex, an important regulator of S-G2 phase
cell cycle transition and the ultimate target of the check-
point signaling pathway, is also inhibited by p21, the
downstream effector of p53 [17].
Scopoletin (6-methoxy-7-hydroxycoumarin), a natural
compound originating from Erycibe obtusifolia Benth andother plants, has been proven to possess a wide range of
pharmacological properties, such as anti-angiogenic,
anti-inflammatory, hypouricemic and anti-tumor acti-
vities [18-20]. It exerted antitumor effects on human
prostate tumor cells and leukemia cells through indu-
cing cell cycle arrest and triggering apoptosis [21,22],
and also showed considerable therapeutic potentials
against 7, 12-dimethylbenz anthracene-induced skin can-
cer in mice [23]. Whereas, scopoletin has been demon-
strated to exert far less profound effects in vitro and
in vivo, and high in vivo elimination rate leads its effect to
maintain only a few minutes. Moreover, recent studies
have indicated that some derivatives of scopoletin could
exhibit good antitumor effects in vitro and in vivo [24].
Recently, we synthesized a series of new scopoletin deriv-
atives with different substituents. These derivatives were
screened for in vitro cytotoxic activity against human can-
cer cell lines representing cancers of lung, colon, ovary as
well as breast. Compared with doxorubicin, a standard po-
tent anticancer drug, compound SC-III3 ((E)-3-(4-chloro-
phenyl)-N-(7-hydroxy-6-methoxy-2-oxo-2H-chromen-3-yl)
acrylamide, Figure 1) showed potent anticancer activity
at low concentrations against most of the used human
tumor cell lines in vitro, and inhibition of the trans-
planted mouse lewis lung carcinomas in vivo [Li LH,
Zhao P, Xia YF, Chen L: Synthesis, in vitro and in vivo
antitumor activity of scopoletin-cinnamic acid hybrids,
submitted]. In the present study, we investigated the anti-
tumor effects of SC-III3 in hepatocellular carcinoma cells
and a xenograft model of nude mice, and shed light on its
possible mechanisms in views of oxidative DNA damage




2-oxo-2H-chromen-3-yl) acrylamide, was prepared by
Dr. Chen Li (China Pharmaceutical University, China).
The structure was identified by IR, 1H NMR, and HRMS.
The purity was 99.51% determined with HPLC. It was
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10 mM and stored at −20°C. The concentrations used
here were 0.03, 0.1, 0.3 and 1 μM for cellular treatment
in vitro and freshly diluted with DMEM to final concen-
tration. Cells in control groups were treated with the same
amount of DMSO (0.01%) as used in the corresponding
experiments. Doxorubicin was obtained from Shenzhen
Main Luck Pharmaceuticals, Inc. (Shenzhen, China) and
dissolved in phosphate buffered saline (PBS) to give a stock
solution of 10 mmol/L. The solution was stored at −20°C,
and kept away from light. MTT [3-(4, 5-dimethylthiazol-2-
yl)-2, 5-dipheny-tetrazoliumbromide], N-acetyl-l-cysteine
(NAC), Ku55933 and UCN-01 were obtained from Sigma-
Aldrich (St. Louis, USA) and applied in 0.01 M PBS. Anti-
bodies against p-ATM (Ser1981), ATM, p-ATR (Ser428),
ATR, p-Chk1 (Ser345), p-Chk1 (Ser280), p-Chk1 (Ser296),
Chk1, p-Cdk2 (Tyr15), p53, p21 were purchased from Cell
Signaling Technology (Danvers, MA). p-Chk2 (Thr68),
Chk2, Cdc25A, p-H2AX(Ser139), H2AX antibodies were
purchased from EnoGene Biotech (Nanjing, China),
GAPDH monoclonal antibodies were purchased from
Kangchen Bio-tech (Shanghai, China); Cdk2, cyclinA,
cyclinE, cyclinB, Bax, Bcl-2 monoclonal antibodies were
purchased from Bioworld (Georgia, USA).
Cell culture and animals
The human hepatoma HepG2 cell line was obtained
from American Type Culture Collection (Bethesda, MD,
USA). Cells were grown in DMEM medium (Gibco,
USA) supplemented with 10% fetal bovine serum (Bio-
logical Industries, Israel), 100 units/mL penicillin and
60 μg/mL streptomycin (Gibco, USA) at 37°C in a hu-
midified atmosphere comprised of 95% air and 5% CO2.
Human normal liver cell LO2 was purchased from the
Cell Bank of the Chinese Academy of Sciences (Shang-
hai, China). Cells were grown in RPMI-1640 medium
(Gibco, USA) supplemented with 10% fetal bovine serum
(Biological Industries, Israel). Exponentially growing cul-
ture was maintained in a humidified atmosphere com-
prised of 95% air and 5% CO2 at 37°C.
Specific pathogen-free male BALB/c nude mice,
weighing 18–22 g, between 4 and 6 weeks of age, were
purchased from Shanghai Slac Laboratory Animal Co.
LTD (Shanghai, China). The mice were raised under
controlled temperature (26-28°C, 55 ± 5% humidity) and
daily light intensity (12 h of light), and were fed with
standard laboratory food and water adlibitum. The ani-
mal experiments were conducted with the approval of
the Animal Ethics Committee of China Pharmaceutical
University.
MTT assay
The HepG2 cells were initiated in 96-well microplate at
a density of 5 × 103 cells per well in 100 μL culturemedium. The cells were incubated overnight and then
treated with various concentrations of SC-III3 or doxo-
rubicin, and cultured for 24 or 48 h. Subsequently,
20 μL/well of MTT solution (5 mg/mL) was added to
each well. Plate was incubated at 37°C in a 5% CO2
atmosphere for 4 h, the supernatants were removed and
150 μL/well DMSO was added to dissolve formazan
crystals. Plate was placed on an orbital shaker for 5 min,
and the absorbance per well was recorded at 570 nm
with a Model 1500 Multiskan spectrum microplate
Reader (Thermo, Waltham, MA, USA). Data were ana-
lyzed from three independent experiments and then nor-
malized to the absorbance of the wells containing media
only (0%) and untreated cells (100%). IC50 value was
taken as the concentration that caused 50% inhibition of
cell viabilities and calculated by Graph pad Prism 5
software.
Cell cycle analysis
HepG2 cells were treated with various concentrations of
SC-III3 and were harvested by trypsinization, fixed with
70% ethanol and stored at −20°C for at least 1 day. Fol-
lowing fixation, cells were subjected to a PBS wash and
then stained with DNA staining solution comprising
2.5 mg/mL propidium iodide (PI) and 50 mg/mL RNase
A in PBS. Samples were incubated at 37°C for 30 min
away from light and then analysed on a FACSCanto II
flow cytometer (FACSCanto II, Becton Dickinson, USA).
Apoptosis detection
HepG2 cells were treated with various concentrations of
SC-III3 and were harvested by trypsinization and then
washed twice with PBS. Cells were stained with Annexin
V-FITC and PI, and loaded on a flow cytometer, set for
FL1 (AnnexinV) and FL2 (PI) bivariate analysis Data ac-
quisition and analysis were performed with a Becton–
Dickinson FACSCalibur flow cytometer using Cell Quest
software.
Western blotting assay
HepG2 cells were treated with different concentrations of
SC-III3 (0.03, 0.1, 0.3 and 1 μM) for 24 or 48 h. Subse-
quently, cells were washed twice with ice-cold PBS buffer
(pH 7.2). Cells were lysed with lysis buffer (15 mM Tris
[tris (hydro xymethyl) aminomethane] - HCl, 50 mM
NaCl, 5 mM EGTA [ethyleneglycoltetraacetic acid], 1%
TritonX-100, 1% sodium deoxycholate, 0.1% SDS [sodium
dodecyl sulfate], 1 mM NaF, 1 mM PMSF [phenylmethyl-
sulfonyl fluoride], 1 mM Na3VO4, 10 μg/mL aprotinin,
and 10 μg/mL leupeptin, pH 7.4) and centrifuged. The
concentration of total proteins was measured by Bradford
assay with a Varioskan spectrofluorometer and spectropho-
tometer (Thermo, Waltham, Massachusetts) at 595 nm.
Samples were fractionated on a 10% SDS-PAGE, stacked at
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ferred to PVDF membranes at 15 V. Membranes were
blocked for 1 h at room temperature with 5% nonfat-milk
and then incubated with different primary antibodies over-
night at 4°C. Then, they were incubated with secondary
antibodies for 1 h at 37°C. The bands were visualized using
film exposure with ECL reagent.
Measurement of ROS level
The production of cellular reactive oxygen species (ROS)
was detected using fluorescent dye 2, 7-dichlorofluorescein-
diacetate (DCFH-DA, Beyotime Institute of Biotechnology,
China) sensitively as previously described [25]. In brief,
the HepG2 cells were pretreated with/without NAC for
2 h and then exposed to SC-III3 for 12 h. Then cells were
collected and incubated with 10 μM DCFH-DA atte-
nuated with serum-free medium for 30 min at 37°C in the
dark. After washed by serum-free, ROS level was mea-
sured by the intensity of the fluorescence on a Model
1500 Multiskan spectrum microplate Reader (Thermo,
Waltham, MA, USA).
Animal study
After acclimatized to their new environment for 1 week,
the mice were injected subcutaneously with HepG2 cells
(4 × 106/0.2 mL/mouse) into the right flank. When
tumors reached a mean group size of approximately
100 mm3, the mice were randomly divided into five
groups with 10 mice each (day 0). Then mice were
treated by intraperitoneal injection of solvent (0.5%
CMC-Na), SC-III3 (2.5, 5 and 10 mg/kg) or doxoru-
bicine (2.5 mg/kg) every day for 2 weeks. Tumor volume
was measured every 3 days. The tumor volume was cal-
culated by the formula 1/2 × larger Diameter × (smaller
diameter)2. At the 15th day, all mice were killed and the
tumors were segregated, weighed and stored in −80°C.
Tumor inhibitory ratio was calculated by the following for-
mula: Tumor inhibitory ratio (%) = [(Wcontrol - Wtreated)/
Wcontrol] × 100%. Wtreated and Wcontrol were the average
tumor weight of the treated and control group, respec-
tively [26].
Statistical analysis
For analysis of data, values were presented as mean ± SEM
for three independent experiments. The differences bet-
ween the groups were examined for statistical significance
using non-paired Student’s two-tailed t test with Prism 5
software.
Results
SC-III3 inhibited the growth of human liver cancer cells
in vitro and in vivo
At first, we examined the effect of SC-III3 at different
concentrations on cell viability. As shown in Figure 2A,after 24 h and 48 h of treatment, SC-III3 obviously re-
duced the number of viable cells, and the IC50 values
were 0.65 and 0.32 μM, respectively. In contrast, a
normal liver cell line LO2 was less sensitive to SC-III3
(Figure 2B). HepG2 and control LO2 cells were also
treated with increasing concentrations of doxorubicin
(DOX), a broad-spectrum chemotherapeutic drug, for 24
and 48 h. DOX caused a concentration-dependent de-
crease in HepG2 cell viability with an IC50 value of
3.1 μM at 24 h and 1.2 μM at 48 h (Figure 2C). Mean-
while, DOX also significantly decreased LO2 cell ability
with an IC50 of 3.5 μM at 24 h and 0.92 μM at 48 h
(Figure 2D). Our data showed that SC-III3 significantly
suppressed the proliferation of liver cancer cells within a
48 h period, but it had no effect on normal liver cells
distinct from DOX.
The ability of SC-III3 in killing HepG2 cells in vitro led
us to evaluate its anti-tumor activity in vivo. A xenograft
mouse model of HepG2 cells was therefore established
(Figure 3A). The results showed that SC-III3 significantly
inhibited tumor growth during the 14-day experimental
period in a dose-dependent manner (Figure 3B). As shown
in Figure 3C and 3D, compared with the control group,
SC-III3 significantly reduced the tumor weight. And the
inhibition rates caused by SC-III3 (2.5, 5 and 10 mg/kg)
were 31.2, 38.6, and 52.4%, respectively. Meanwhile,
mouse body weights were lack of significant difference
between SC-III3-treated and control groups during the
experiment. The tumor growth inhibition rate of DOX
group was 81.5%. However, DOX treatment significantly
reduced the mouse body weight. These data demonstrated
that SC-III3 inhibited tumor growth of HepG2 xenograft
mouse model in a dose-dependent manner without sig-
nificant side effect.
SC-III3 induced S cell cycle arrest in liver cancer cells
Whether the antiproliferative activities of SC-III3 was due
to the induction of cell cycle arrest was addressed. After
treated with various concentrations of SC-III3 for 24 and
48 h, respectively, HepG2 cells were fixed. Then cell cycle
populations were determined by flow cytometry. As
shown in Figure 4, after SC-III3 (0.03, 0.1, 0.3, 1 μM)
treatment for 24 h, the cell percentages at S phase were
increased from 30.3 ± 3.1% to 34.3 ± 3.3%, 42.1 ± 2.4%,
45.6 ± 1.5%, and 50.9 ± 2.9%, respectively (Figure 4A, B);
For 48 h, the cell percentage at S phase were increased
from 31.1 ± 1.5% to 38.6 ± 3.2%, 57.9 ± 1.3%, 65.3 ± 2.3%,
and 70.6 ± 2.4%, respectively (Figure 4C, D). The results
showed that SC-III3 induced a time- and concentration-
dependent S phase arrest significantly. Western blot assay
indicated that SC-III3 treatment for 24 h resulted in a
concentration-dependent reduction of the expressions of
cyclin A, cyclin B, cyclin E and Cdk2 (S cell cycle regu-
lators) in HepG2 cells (Figure 4E). These studies suggested
Figure 2 SC-III3 inhibited cell growth of HepG2 cells. (A) HepG2 cells were treated with SC-III3 for 24 and 48 h, and cell viability was analyzed
by MTT assay. (B) LO2 cells were treated with SC-III3 for 24 and 48 h. (C) HepG2 cells were treated with doxorubicin (DOX) for 24 and 48 h.
(D) LO2 cells were treated with DOX for 24 and 48 h. Data were presented as means ± SEM of three separate experiments. The difference were
significant at *p < 0.05, **p < 0.01 vs. control.
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with the induction of S phase arrest.
SC-III3 caused apoptosis of liver cancer cells
On the basis of the S phase arrest caused by SC-III3, we
further examined the apoptosis rate of HepG2 cells by
flow cytometry analysis. As shown in Figure 5, after
treated with SC-III3 (1 μM) for 24 h, the apoptotic rate of
HepG2 cells was less than 15% (Figure 5A, B). While ex-
posed to SC-III3 (0.03, 0.1, 0.3 and 1 μM) for 48 h, the
apoptotic percentages of HepG2 cells were increased to
15.9 ± 3.8%, 24.4 ± 2.6%, 27.1 ± 1.4%, and 28.9 ± 1.3%, re-
spectively (Figure 5C, D). Then we further evaluated the
levels of apoptosis-related proteins in HepG2 cells treated
with SC-III3 for 48 h. As shown in Figure 5E, SC-III3
could reduce the expression of Bcl-2 but concomitantly
increase the expression of Bax. It was suggested that
SC-III3 might mainly interfere with the cell cycle of
HepG2 cells, which in turn led to slight cell apoptosis.SC-III3 induced DNA damage response and the activation
of ATM/Chk pathway
Because DNA damage was strongly correlated with the
progression of cells through the S phase of the cell cycle
[12], we assumed that SC-III3-induced S-phase arrest of
HepG2 cells was due to the damage of DNA. To verify
this point, we investigated the phosphorylations of his-
tone variant H2AX at Ser-139 and Chk1 at both Ser-280
and Ser-296, the indicators of DNA breaks. SC-III3
markedly increased the levels of phosphorylated H2AX
at Ser-139 and Chk1 at Ser-280 in a concentration-
dependent manner, whereas did not affect the phospho-
rylation of Chk1 at Ser-296. These results indicated that
SC-III3 substantially led to DNA damage in HepG2 cells
(Figure 6A).
Among DNA damage response network, ATM and
ATR play central roles [13,14]. The regulation of Chk1/2
and p53 function is the best known pathway by which
ATM and ATR regulate the cell cycle. The changes of
Figure 3 SC-III3 markedly inhibited tumor growth in vivo. Mice were intraperitoneally injected with 2.5, 5 and 10 mg/kg of SC-III3 once a
day for 14 days. Control was treated with normal vehicle, and positive control was intraperitoneally injected with 2.5 mg/kg of doxorubicin.
(A) Resected tumor images from the experimental. (B) Tumor volume was measured every 3 days. (C) Tumor mass were weighed. (D) Nude mice
weight was recorded once a day. Data were presented as Mean ± SEM, n = 10. The difference were significant at *p < 0.05, **p < 0.01 vs. control.
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naling, including ATM, ATR, Chk1, Chk2, Cdc25A and
p53, in response to SC-III3 were investigated. As shown
in Figure 6B, exposing HepG2 cells to SC-III3 (0.03, 0.1,
0.3 and 1 μM) for 24 h significantly increased the phos-
phorylation levels of ATM at Ser1981, Chk1 at Ser345,
Chk2 at Thr68 and Cdk2 at Tyr15, increased the protein
levels of p53, p21 and decreased Cdc25A, while did not
affect the protein levels of ATM, ATR, Chk1 and Chk2
and the phosphorylation levels of ATR at Ser428.
Time-course for SC-III3 (1 μM)-induced activation of
ATM pathway of HepG2 cells showed that SC-III3 in-
creased the phosphorylation level of ATM (Ser1981) at
3 h, which persisted up to 24 h, then slightly declined at
48 h. The phosphorylations of Chk1 (Ser345) and Chk2
(Thr68) were also increased by SC-III3 treatment for
6 h, and maintained the elevated levels up to 24 h. The
Cdc25A, a phosphatase that plays a critical role in G1-S
transition and S-phase progression, was down-regulated
at 6 h after SC-III3 exposure in HepG2 cells. This mo-
dulation was consistent with the activation of Chk1 and
Chk2. The protein levels of p53 and p21 were increased
at 6 and 12 h, respectively. Meanwhile, SC-III3 induced
slightly accumulation of phospho-Cdk2 (Tyr15) at 12 h,
which persisted up to 48 h in HepG2 cells (Figure 6C).
These results suggested that the activation of ATM-
Chk1/Chk2-Cdc25A-Cdk2 and p53-p21 pathways are in-
volved in the effect of SC-III3.Inhibitors of ATM and Chk1/Chk2 reversed the S phase
arrest by SC-III3
To gain insight into the relative contribution of ATM-
Chk1/Chk2 pathway in SC-III3-mediated S phase arrest,
Ku55933 (an inhibitor of ATM) and UCN-01 (an inhibitor
of Chk1 and Chk2) were adopted, respectively [27,28]. As
shown in Figure 7A and 7B, Ku55933 treatment com-
pletely abrogated SC-III3-induced S phase arrest. The
effect of Ku55933 on the activation of Chk1/2-Cdc25A-
Cdk2 and p53-p21 pathway in response to SC-III3 treat-
ment was further investigated. It was shown that Ku55933
could suppress the phosphorylations of ATM on Ser1981,
Chk1 on Ser345, Chk2 on Thr68, and Cdk2 on Tyr15
induced by SC-III3. Meanwhile, SC-III3-mediated expres-
sions of p53 and p21 (downstream effectors of ATM) were
down-regulated by Ku55933. Furthermore, the down-
regulated expression of Cdc25A by SC-III3 was also re-
versed by Ku55933 (Figure 7C). Similar to Ku55933,
UCN-01 also dramatically reversed the S arrest of HepG2
cells by SC-III3 (Figure 7A, B). Furthermore, compared
with SC-III3-treated group, a dramatic increase of Cdc25A
and decreased phosphorylations of Chk1 on Ser345, Chk2
on Thr68, Cdk2 on Tyr15 were observed in the group co-
treated with UCN-01 and SC-III3 (Figure 7D). Together,
these data demonstrated that ATM-Chk1/Chk2 and their
downstream signals were rapidly activated in HepG2 cells
by SC-III3 exposure, and these signals might play critical
roles in SC-III3-induced S arrest.
Figure 4 SC-III3 induced HepG2 cell cycle arrest. (A, B) The cells were treated with SC-III3 for 24 h, and the cell cycle was tested by flow
cytometry after staining with propidium iodide. Cells in G0/G1, S, and G2/M phases were quantified and presented. (C, D) The cells were treated with
SC-III3 for 48 h. (E) HepG2 cells were treated with SC-III3 for 24 h. The protein levels of Cyclin A, Cyclin B, Cyclin E and Cdk2 were analyzed with western
blotting. Data were presented as means ± SEM of three separate experiments. The difference were significant at *p < 0.05, **p < 0.01 vs. control.
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High levels of ROS can induce DNA damage, cell cycle
arrest and apoptosis [9,29]. To investigate the effect of
SC-III3 on ROS generation, we detected the levels of
ROS in SC-III3-treated cells. It was shown that SC-III3
induced a substantial increase in ROS levels in HepG2
cells. In addition, NAC, a ROS scavenger, significantly
reduced the accumulation of ROS induced by SC-III3
(Figure 8A). In contrast, SC-III3 did not cause an sig-
nificant increase in ROS levels in normal cells LO2
(Figure 8B). To further investigate whether the gene-
ration of ROS was a crucial step in SC-III3-induced
DNA break, ATM-Chk pathway activation and S phase
arrest, HepG2 cells were pretreated with/without NAC
and then exposed to SC-III3. NAC pretreatment almostcompletely abrogated the ability of SC-III3 to promote
the phosphorylation of H2AX, a well-known indicator in
response to DNA damage, and in activating ATM-Chk1/
Chk2-Cdc25A and p53-p21 pathways (Figure 8C). Fur-
thermore, SC-III3-caused cell cycle arrest and cell via-
bility decrease were also significantly blocked by NAC
(Figure 8D, E, F). These results indicated that ROS me-
diated the DNA damage induced by SC-III3, and ROS
activated S phase checkpoint through ATM-activated
Chk1/Chk2-Cdc25A and p53-p21 pathway.
Discussion
Hepatocellular carcinoma (HCC), which has highly
chemical-resistant to currently available chemotherapeu-
tic agents, is one of the most common causes of cancer
Figure 5 SC-III3 induced HepG2 apoptosis in HepG2 cells. (A, B) Cells were treated with SC-III3 for 24 h. Annexin V/PI double-staining assay
of HepG2 was analyzed by flow cytometry. The percentages of cells in apoptosis were represented. (C, D) Cells were treated with SC-III3 for 48 h.
(E) HepG2 cells were treated with SC-III3 for 48 h. The protein levels of Bcl-2 and Bax were analyzed with western blotting. Data were presented
as means ± SEM of three separate experiments. The difference were significant at *p < 0.05, **p < 0.01 vs. control.
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recognized as a new source of anticancer drugs as new
chemotherapy adjuvant by enhancing the efficacy and
diminishing the side effects of chemotherapies. Scopole-
tin is the main active constituent of E. obtusifolia Benth
stems and exerts anti-inflammation, anti-angiogenesis
and anti-cancer effects [18,19,21-24]. We modified the
structure of scopoletin and finally obtained a new com-
pound, named SC-III3. In this study, SC-III3 showed
significant inhibitory effect on the growth of HepG2
cells in vitro and the HepG2 xenografts in vivo. Then,
we dissected the fundamental mechanisms of SC-III3
fighting against hepatocellular carcinoma: SC-III3 in-
duced ROS-mediated DNA damage, which activatedS phase checkpoint through ATM-activated Chk1/2-
Cdc25A-Cdk2 and p53-p21 cascade.
SC-III3 could significantly inhibit HepG2 cell prolifera-
tion and growth in a concentration- and time-dependent
manner. Low concentrations (0.03-1 μM) of SC-III3
showed significantly inhibitory effect on HepG2 cell pro-
liferation after 24 h and 48 h treatment, which clearly
demonstrated that SC-III3 was a potent cytotoxic com-
pound. But this inhibitory effect is selective, exhibiting
very little effect on the growth of LO2 cell, a normal liver
cell line. In our studies, SC-III3 showed inhibitory effect
on the hepatocellular carcinoma cells xenograft in nude
mice. SC-III3 treatment in nude mice bearing tumors re-
sulted in a significant inhibition of tumor volume without
Figure 6 Effect of SC-III3 on DNA damage and ATM/ATR pathways. (A) HepG2 cells were treated with SC-III3 for 24 hours. Western blot
analysis of p-H2AX, total H2AX, p-Chk1 (Ser280) and p-Chk1 (Ser296) response to SC-III3. (B) HepG2 cells were treated with SC-III3 for 24 hours.
Western blot analyses of the ATM/ATR signaling related proteins in HepG2 cells. (C) HepG2 cells were treated with 1 μM SC-III3 for different times
as indicated. Western blot analyses of p-ATM, p-ATR, p-Chk1, p-Chk2, Cdc25C, p-CDK2, p53, and p21 in HepG2 cells. These experiments were done
in triplicates.
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http://www.biomedcentral.com/1471-2407/14/987any apparent sign of toxicity. DOX administration also
significantly inhibited the tumor growth of HepG2 xeno-
graft, but caused serious side effects to the mice.
Cancer is considered a disease of the cell cycle. This
assessment is supported by the fact that normal cells
only proliferate in response to growth stimuli and spe-
cific mitogenic signals, but cancer cells proliferate in an
unregulated way. Moreover, new links between alter-
ations in the cell cycle regulatory machinery and tumo-
rigenesis are being constantly reported and virtually all
molecular species involved in regulating cell prolife-
ration described in the literature have been related tomalignant transformation [31]. Therefore, we assumed
that SC-III3-induced cell growth inhibition was due to
the cell cycle arrest. In the present study, we found that
SC-III3 induced dose-dependent S-phase cell cycle arrest
in HepG2 cells (Figure 3A). Cycle progression is con-
trolled by several cyclin-dependent kinases (Cdks) and
their cyclin partners. A number of Cdks regulate the cell
cycle event in mammalian cells. Among the Cdks that
regulate cell cycle progression, Cdk2 kinases is activated
primarily in association with cyclin A, cyclin B and cyc-
lin E in the S-phase progression [30-33]. In this study,
cell cycle analysis revealed a prominent S-phase arrest of
Figure 7 Role of ATM/Chk1/Chk2 in SC-III3-mediated S cell cycle arrest. (A, B) HepG2 cells were exposed to 1 μM SC-III3 for 24 h with or
without adding of 10 μM Ku55933 or 0.3 μM UCN-01. Then, cells were analyzed for cell cycle distribution by flow cytometry. Cells in G0/G1, S,
and G2/M phases were quantified and presented. (C) HepG2 cells were exposed to 1 μM SC-III3 with or without adding of 10 μM Ku55933 for
24 h. Then, western blot analyses of p-ATM, p-ATR, p-Chk1, p-Chk2, Cdc25C, p-CDK2, p53, and p21 in HepG2 cells. (D) HepG2 cells were exposed
to 1 μM SC-III3 with or without adding of 0.3 μM UCN-01 for 24 h. Then, western blot analyses of p-Chk1, p-Chk2, p-Cdk2, and Cdc25A in HepG2
cells. The Data were presented as mean ± SEM for three separate experiments. The difference were significant at **p < 0.01 compared with SC-III3
(1 μM) and ##p < 0.01 compared with SC-III3 (0 μM).
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http://www.biomedcentral.com/1471-2407/14/987SC-III3-treated cells, and Cdk2, cyclin A, cyclin B and
cyclin E proteins were down-regulated by SC-III3 treat-
ment (Figure 4).
In advanced HCC, cancer cells usually become resis-
tant to apoptosis [5,6]. Thus, identification of SC-III3
that can induce apoptosis in HCC cells is highly desir-
able. The results demonstrated that treatment of HepG2
cells with SC-III3 for 48 h led to an elevated expression
of Bax and reduced expression of Bcl-2, and then in-
creased the ratio of Bax/Bcl-2, which contributed to
SC-III3-induced apoptosis of HepG2 cells.
Treatment with various concentrations of SC-III3 for
24, 48 h significantly induced S phase arrest in HepG2
cells at early time point (24 h). In contrast, flow cyto-
metry analysis revealed that treating HepG2 cells with
1 μM of SC-III3 for 24 h resulted in only a slight in-
crease in apoptosis, and treating HepG2 cells with 1 μM
of SC-III3 for 48 h led to a moderate increase in apop-
tosis. Such findings suggest that SC-III3 mainly sup-
pressed the HepG2 cell cycle, which in turn led to
induction of cell apoptosis.
We continued to investigate the detailed molecular
mechanism of SC-III3-induced S cell cycle arrest and
apoptosis in HepG2 cells. Many drugs in use disrupt
genome integrity by causing DNA strand breaks, and
consequently block cell proliferation mainly by inhibitingfactors that enable cells to proceed from one cell cycle
phase to the next through checkpoints in the cell div-
ision cycle [34]. ATM and ATR play key roles in DNA
damage response. Generally, ATM is primarily activated
in response to DNA strand breaks, such as those in-
duced by ionizing radiation, whereas ATR is predomi-
nantly activated in response to damage caused by UV
rays or replication block. The downstream effectors such
as Chk1, Chk2 and p53 were activated by ATM and
ATR [13,14]. For instance, Chk2 was activated by phos-
phorylation at Thr68 by ATM, while Chk1 activation re-
quires phosphorylation at Ser317 and Ser345 catalyzed
by ATM and/or ATR. Furthermore, the activated Chk1
and Chk2 phosphorylate their downstream effectors
such as Cdc25A which regulate the activity of the Cdk2
by dephosphorylating on Tyr15. Although ATM primar-
ily phosphorylates the Chk2, while ATR preferentially
phosphorylates the Chk1, accumulating evidences indi-
cated that a cross-talk occurs between the two pathways
[15-17]. Cdk2-cyclinA complexes, critical S phase regu-
lator, were inhibited by p21, the downstream effector of
p53. Then, we hypothesized that SC-III3 induced DNA
damage, leading to S cell cycle arrest and apoptosis
responses. The data demonstrated that SC-III3 induced
DNA damage in HepG2 cells in a concentration- and
time-dependent manners as confirmed by the upregulated
Figure 8 SC-III3 induced DNA damage by activation of ATM pathway via ROS generation. (A) HepG2 cells were pretreated with/without
NAC for 2 h and then exposed to SC-III3 for 12 h. ROS level was determined with fluorescence probe DCFH2-DA. (B) LO2 cells were exposed to
SC-III3 for 12 h. (C) HepG2 cells were pretreated with/without NAC for 2 h and then exposed to SC-III3 for 24 h. Then, cell lysates were prepared
for Western blotting. (D, E) HepG2 cells were pretreated with/without NAC for 2 h and then exposed to SC-III3 for 24 h. Then, cells were analyzed
for cell cycle distribution by flow cytometry. Cells in G0/G1, S, and G2/M phases were quantified and presented. (F) HepG2 cells were pretreated
with/without NAC for 2 h and then exposed to SC-III3 for 24 h. Then, cell viability was analyzed by MTT assay. Data were presented as mean ±
SEM for three separate experiments. The difference were significant at **p < 0.01 compared with SC-III3 (1 μM) and ##p < 0.01 compared with
SC-III3 (0 μM).
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http://www.biomedcentral.com/1471-2407/14/987expression of p-H2AX (Ser-139) and p-Chk1 (Ser-280),
the biomarker for DNA damage. After the generation of
DNA damage, ATM, the main sensor of DNA damage,
was activated by phosphorylation at its serine 1981 in SC-
III3-treated cells. The ATM inhibitor, Ku55933, reversed
the S arrest and ATM-Chk1/Chk2-Cdc25A-Cdk2 and
p53-p21 activation triggered by SC-III3, the results
showed a causal link between ATM activation and S arrest
in the treated cancer cells. Because both the checkpoint
kinases Chk1 and Chk2 are the immediate substrates of
ATM [35], our data showed that ATM significantly acti-
vates them by phosphorylation. Inhibiting Chk1/Chk2 by
UCN-01 could abolish SC-III3-induced S phase arrest and
S checkpoint, which indicated that these two kinases also
contribute to the S arrest induced by SC-III3 in HepG2
cells. Thus, our data reveal the mechanism whereby
SC-III3 induces S arrest and the existence of a mecha-
nistic link between the SC-III3-caused DNA damage sig-
nals and the activation of the ATM-Chk1/2 pathway
leading to the S arrest.It is known that the therapeutic effect of many anti-
cancer drugs is related to generation of intracellular
ROS. Furthermore, ROS induced oxidative DNA damage
has been well established. In normal cells, ROS are at
low levels, which is pivotal for the modulation of normal
cell proliferation. While, tumor cells, with a higher level
of ROS close to the threshold of cytotoxicity, are suscep-
tible to ROS-generating agents [9,36,37]. In this study,
we found that SC-III3 caused a marked increase in ROS
levels in HepG2 cells, which could be almost completely
suppressed by NAC. In contrast to the results in HepG2
cells, SC-III3 did not cause an significant increase in
ROS levels in normal cells. This selective generation of
ROS in cancer cells distinguishes SC-III3 from other
small molecules that affect ROS levels, such as paclitaxel
and doxorubicin, which is suggestive of a selective
mechanism of inhibition of HepG2 by SC-III3 [38,39].
NAC pretreatment almost completely block SC-III3-
induced p-H2AX expression and DNA damage response
pathways, suggesting that SC-III3-induced DNA damage
Zhao et al. BMC Cancer 2014, 14:987 Page 12 of 13
http://www.biomedcentral.com/1471-2407/14/987was ROS dependent. Furthermore, SC-III3-induced HepG2
cells S phase arrest and cell viability decrease were also
reversed by NAC pretreatment. Collectively, these data
demonstrated that SC-III3 mediated DNA damage and
subsequent S phase arrest through inducing intracellu-
lar ROS generation.
Conclusions
In summary, we demonstrated that cell growth inhibition
and S phase arrest could occur in HepG2 cells exposed to
SC-III3, and that these changes were mediated by ROS
generation, which in turn activated ATM-Chk1/2-Cdc25A-
Cdk2 pathway joined by ATM-p53-p21 branch, leading to
the S phase arrest. Furthermore, SC-III3 also inhibited
tumor growth of HepG2 xenograft mouse model. These
data provided new insights into the anti-cancer mecha-
nisms of SC-III3 and related compounds, which may be
helpful to the development of SC-III3 into a promising
therapeutic agent against hepatocellular carcinoma cancer.
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